Literature DB >> 31352382

Subcutaneous mass concerning for sarcoma: a peculiar presentation of diffuse large B-cell lymphoma.

John Mayo1, Kenneth Bogenberger1, Thomas Raj1, Jeffrey Reha1.   

Abstract

Diffuse large B-cell lymphoma (DLBCL) can present in a number of different ways, including as a primary cutaneous lesion or at various other extranodal sites. However, it is rare for a DLBCL to present as a clinically subcutaneous mass without visible skin changes or nodal involvement. A 36-year-old man presented with a 4×4×1 cm subcutaneous mass to his shoulder with normal overlying skin which had been enlarging over 6 months. Physical exam and imaging together made a strong case for sarcoma, and the patient underwent a radical resection. The final pathological diagnosis returned as a diffuse B-cell lymphoma (germinal centre type). The patient subsequently healed and tolerated chemotherapy well. DLBCL can masquerade as a soft tissue mass at initial presentation. If the diagnosis is not clear, a biopsy should be pursued. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cancer intervention; oncology; surgical diagnostic tests; surgical oncology

Mesh:

Year:  2019        PMID: 31352382      PMCID: PMC6663184          DOI: 10.1136/bcr-2019-229327

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation--a population-based study of 1575 cases.

Authors:  Michael B Møller; Niels T Pedersen; Bjarne E Christensen
Journal:  Br J Haematol       Date:  2004-01       Impact factor: 6.998

2.  Subcutaneous diffuse large B-cell lymphoma with intraocular involvement.

Authors:  Ming Chi; Nora Bucher; Anna Gabrielian; Mathew W MacCumber; Teresita Zdunek
Journal:  Future Oncol       Date:  2012-06       Impact factor: 3.404

3.  Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  H Tilly; M Gomes da Silva; U Vitolo; A Jack; M Meignan; A Lopez-Guillermo; J Walewski; M André; P W Johnson; M Pfreundschuh; M Ladetto
Journal:  Ann Oncol       Date:  2015-09       Impact factor: 32.976

4.  Bilateral cutaneous diffuse large B-cell lymphoma on FDG PET/CT.

Authors:  Ebuzer Kalender; Mustafa Yilmaz; Suna Erkilic; Mehmet Yilmaz; Zeki Celen
Journal:  Clin Nucl Med       Date:  2011-10       Impact factor: 7.794

5.  Multiple Subcutaneous Nodules as Initial Presentation of Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL) Detected by PET/CT.

Authors:  Guohua Shen; Ying Kou; Bin Liu; Anren Kuang
Journal:  Clin Nucl Med       Date:  2018-10       Impact factor: 7.794

6.  Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.

Authors:  Laurie H Sehn; Jane Donaldson; Mukesh Chhanabhai; Catherine Fitzgerald; Karamjit Gill; Richard Klasa; Nicol MacPherson; Susan O'Reilly; John J Spinelli; Judy Sutherland; Kenneth S Wilson; Randy D Gascoyne; Joseph M Connors
Journal:  J Clin Oncol       Date:  2005-06-13       Impact factor: 44.544

7.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.

Authors:  A A Alizadeh; M B Eisen; R E Davis; C Ma; I S Lossos; A Rosenwald; J C Boldrick; H Sabet; T Tran; X Yu; J I Powell; L Yang; G E Marti; T Moore; J Hudson; L Lu; D B Lewis; R Tibshirani; G Sherlock; W C Chan; T C Greiner; D D Weisenburger; J O Armitage; R Warnke; R Levy; W Wilson; M R Grever; J C Byrd; D Botstein; P O Brown; L M Staudt
Journal:  Nature       Date:  2000-02-03       Impact factor: 49.962

8.  Primary cutaneous diffuse large B-cell lymphoma: prognostic significance of clinicopathological subtypes.

Authors:  John R Goodlad; Andrew S Krajewski; Paul J Batstone; Pam McKay; Jo M White; E Claire Benton; Gina M Kavanagh; Helen H Lucraft
Journal:  Am J Surg Pathol       Date:  2003-12       Impact factor: 6.394

9.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

Authors:  Andreas Rosenwald; George Wright; Wing C Chan; Joseph M Connors; Elias Campo; Richard I Fisher; Randy D Gascoyne; H Konrad Muller-Hermelink; Erlend B Smeland; Jena M Giltnane; Elaine M Hurt; Hong Zhao; Lauren Averett; Liming Yang; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; John Powell; Patricia L Duffey; Dan L Longo; Timothy C Greiner; Dennis D Weisenburger; Warren G Sanger; Bhavana J Dave; James C Lynch; Julie Vose; James O Armitage; Emilio Montserrat; Armando López-Guillermo; Thomas M Grogan; Thomas P Miller; Michel LeBlanc; German Ott; Stein Kvaloy; Jan Delabie; Harald Holte; Peter Krajci; Trond Stokke; Louis M Staudt
Journal:  N Engl J Med       Date:  2002-06-20       Impact factor: 91.245

10.  Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network.

Authors:  A Smith; S Crouch; S Lax; J Li; D Painter; D Howell; R Patmore; A Jack; E Roman
Journal:  Br J Cancer       Date:  2015-03-24       Impact factor: 7.640

  10 in total
  1 in total

1.  Diffuse Large B-Cell Lymphoma of the Left Upper Extremity Mimicking a Sarcoma.

Authors:  Raheel S Siddiqui; Debra Ferman; Sandeep Tuli; M Margaret Kemeny
Journal:  Cureus       Date:  2021-06-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.